Pharming Group N.V. ADS, each representing 10 ordinary shares (PHAR) Stock Price

PHARStock

$9.36−26.23%52W

Market Cap$662.48M

P/E240.70x

PEG Ratio—

Div yield—

Beta-0.04

PHAR Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)-53.78%

Price vs S&P 500 (4W)-8.37%

VGM Score46.24

P/E Ratio (Annual)240.70x

P/CF (Annual)12.54x

Book Value / Share (Quarterly)$0.38

P/TBV (Annual)7.57x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)22.30%

Cash Flow / Share (Quarterly)$0.21

Price vs S&P 500 (YTD)-51.79%

Gross Margin (TTM)86.53%

Net Profit Margin (TTM)2.54%

EPS (TTM)$0.02

10-Day Avg Trading Volume5.57M

EPS Excl Extra (TTM)$0.02

Revenue Growth (5Y)12.13%

EPS (Annual)$0.00

ROI (Annual)0.73%

Gross Margin (Annual)87.90%

Net Profit Margin (5Y Avg)1.43%

Cash / Share (Quarterly)$0.22

P/E Basic Excl Extra (TTM)73.76x

Revenue Growth QoQ (YoY)-3.23%

EPS Growth (5Y)-41.47%

P/E Normalized (Annual)240.70x

ROA (Last FY)0.57%

Revenue Growth TTM (YoY)7.83%

EBITD / Share (TTM)$0.05

ROE (5Y Avg)1.16%

Operating Margin (TTM)5.03%

Cash Flow / Share (Annual)$0.08

P/B Ratio2.54x

P/B Ratio (Quarterly)3.53x

Net Income / Employee (Annual)$7,000

EV / Revenue (TTM)1.75x

Net Interest Coverage (TTM)1.99x

ROA (TTM)1.93%

EPS Growth QoQ (YoY)-63.24%

EV / EBITDA (TTM)21.00x

EPS Incl Extra (Annual)$0.00

Current Ratio (Annual)2.59x

Quick Ratio (Quarterly)2.31x

3-Month Avg Trading Volume8.46M

52-Week Price Return-26.23%

EV / Free Cash Flow (Annual)11.88x

P/E Incl Extra (TTM)73.76x

Revenue / Employee (TTM)$900,400

Tangible BV / Share (Quarterly)$0.20

P/S Ratio (Annual)1.82x

Asset Turnover (Annual)0.75x

52-Week High$1.82

Operating Margin (5Y Avg)3.49%

EPS Excl Extra (Annual)$0.00

CapEx CAGR (5Y)-45.22%

Tangible BV CAGR (5Y)10.15%

26-Week Price Return-43.87%

Quick Ratio (Annual)1.97x

13-Week Price Return-25.94%

Total Debt / Equity (Annual)0.42x

Current Ratio (Quarterly)3.01x

Enterprise Value$641.00M

Revenue / Share Growth (5Y)10.13%

Asset Turnover (TTM)0.76x

Book Value / Share Growth (5Y)6.58%

Revenue / Employee (Annual)$924,200

Inventory Turnover (Annual)0.75x

Pretax Margin (Annual)3.42%

Cash / Share (Annual)$0.26

3-Month Return Std Dev50.63%

Gross Margin (5Y Avg)89.31%

Net Income / Employee (TTM)$22,900

EBITDA CAGR (5Y)-15.39%

EBITDA Interim CAGR (5Y)-20.30%

ROE (Last FY)1.03%

Net Interest Coverage (Annual)1.99x

EPS Basic Excl Extra (Annual)$0.00

P/FCF (TTM)4.51x

Receivables Turnover (TTM)6.64x

EV / Free Cash Flow (TTM)4.21x

Total Debt / Equity (Quarterly)0.42x

EPS Incl Extra (TTM)$0.02

Receivables Turnover (Annual)9.03x

ROI (TTM)2.39%

P/S Ratio (TTM)1.87x

Pretax Margin (5Y Avg)2.91%

Revenue / Share (Annual)$0.50

Tangible BV / Share (Annual)$0.21

Forward P/E31.03x

Free OCF CAGR (5Y)-4.61%

Price vs S&P 500 (52W)-41.76%

P/E Ratio (TTM)73.76x

Year-to-Date Return-41.23%

5-Day Price Return-4.23%

EPS Normalized (Annual)$0.00

ROA (5Y Avg)0.51%

Net Profit Margin (Annual)0.76%

Month-to-Date Return-5.55%

Cash Flow / Share (TTM)$-0.01

EBITD / Share (Annual)$0.05

EPS Growth (3Y)-41.82%

Operating Margin (Annual)6.87%

LT Debt / Equity (Annual)0.33x

P/CF (TTM)4.49x

ROI (5Y Avg)0.53%

P/E Excl Extra (TTM)73.76x

LT Debt / Equity (Quarterly)0.34x

EPS Basic Excl Extra (TTM)$0.02

P/TBV (Quarterly)6.70x

P/B Ratio (Annual)3.96x

Inventory Turnover (TTM)0.77x

Pretax Margin (TTM)4.32%

Book Value / Share (Annual)$0.39

Price vs S&P 500 (13W)-28.62%

Net Margin Growth (5Y)-46.77%

Beta-0.04x

P/FCF (Annual)12.71x

Revenue / Share (TTM)$0.55

ROE (TTM)3.44%

52-Week Low$0.83

vGradeB

gGradeD

mGradeC

vgmGradeC

PHAR Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Jul 30, 2026	$0.06	$0.00	-96.83%(-$0.06)
Q1 2026	May 7, 2026	$0.00	-$0.07	-7100.00%(-$0.07)
Q4 2025	Mar 12, 2026	$0.01	$0.07	+460.00%(+$0.06)
Q3 2025	Nov 6, 2025	$0.00	$0.01	+122.22%(+$0.01)
Q2 2025	Jul 31, 2025	-$0.01	$0.01	+148.00%(+$0.02)

PHAR Analyst Recommendations

Jun 2026

Jul 2026

Aug 2026

Sep 2026

4.43

Industry Peers — Pharmaceuticals(574)

Symbol	Value Score	Growth Score	Momentum Score	P/S Ratio (TTM)	Revenue Growth TTM (YoY)	Gross Margin (TTM)	EPS Growth (5Y)	Price
PHARPharming Group N.V. ADS, each representing 10 ordinary shares	B	D	C	1.9x	7.8%	86.5%	-41.5%	$9.36
LLYEli Lilly & Co.	D	B	A	14.9x	49.6%	83.4%	27.6%	$1257.03
JNJJohnson & Johnson	D	C	B	6.2x	7.8%	67.7%	14.9%	$255.56
ABBVABBVIE INC.	D	C	A	7.8x	10.4%	72.8%	-2.9%	$285.42
MRKMerck & Co., Inc.	D	C	A	5.4x	4.6%	77.3%	21.2%	$145.95
NVSNovartis AG	C	C	B	4.9x	3.3%	75.0%	15.3%	$150.62
AZNAstraZeneca PLC	C	B	B	4.3x	8.6%	81.3%	21.9%	$165.41
ABTAbbott Laboratories	C	C	B	3.9x	8.1%	56.8%	8.2%	$104.89
NVONovo-Nordisk A/S	B	C	C	3.5x	5.6%	80.7%	20.7%	$38.83
PFEPfizer Inc.	C	D	A	2.6x	-0.2%	74.7%	-3.5%	$29.58
VRTXVertex Pharmaceuticals Inc	D	C	B	10.1x	10.2%	86.0%	8.3%	$499.74
BMYBristol-Myers Squibb Co.	B	B	B	2.5x	3.1%	71.7%	—	$59.75
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	C	C	B	2.3x	5.0%	73.6%	-0.5%	$49.51
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	D	B	1.8x	13.4%	72.8%	-8.2%	$40.61
REGNRegeneron Pharmaceuticals Inc	C	C	A	5.2x	9.3%	86.0%	6.3%	$790.74
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	A	2.1x	3.1%	65.5%	-12.6%	$19.67
TEVATeva Pharmaceutical Industries Limited	D	C	A	2.8x	4.1%	52.9%	—	$41.50
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	6.3x	31.1%	88.5%	—	$369.06
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	A	13.8x	10.0%	—	-12.1%	$60.96
ZTSZOETIS INC.	C	C	B	3.5x	1.4%	71.6%	12.0%	$79.38
ALNYAlnylam Pharmaceuticals, Inc.	D	A	C	6.5x	95.1%	79.7%	—	$231.83
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	3215.5x	-67.6%	81.2%	—	$33.53
UTHRUnited Therapeutics Corp	C	C	B	7.2x	2.5%	86.1%	19.3%	$533.12
GMABGenmab A/S ADS	D	C	A	5.5x	22.3%	93.0%	6.8%	$37.00
VTRSViatris Inc. Common Stock	B	C	A	1.5x	4.4%	40.3%	—	$18.66
INSMInsmed, Inc.	F	A	C	18.5x	185.8%	83.5%	—	$96.27
ASNDAscendis Pharma A/S Ordinary Share	D	A	B	11.9x	113.3%	91.3%	—	$225.25
JAZZJazz Pharmaceuticals, Inc.	B	C	B	3.0x	12.6%	88.4%	-1.4%	$210.23
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	18.2x	202.4%	94.4%	—	$66.39
CORTCorcept Therapeutics Inc.	F	C	A	14.3x	16.0%	98.3%	-0.5%	$110.16
ELANElanco Animal Health Incorporated Common Stock	D	B	B	2.3x	11.9%	55.4%	29.9%	$23.55
SMMTSummit Therapeutics Inc. Common Stock	F	—	C	12187.5x	—	—	—	$14.63
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	C	B	3.1x	-0.9%	61.4%	16.5%	$13.07
BMRNBioMarin Pharmaceuticals Inc	C	C	B	3.1x	11.2%	79.6%	-17.0%	$54.68
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	C	8.1x	149.0%	91.5%	—	$449.74
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	213.8x	2928.4%	—	—	$84.95
CYTKCytokinetics Inc.	F	D	B	127.3x	-21.1%	—	—	$61.95
PTGXProtagonist Therapeutics, Inc	F	B	B	29.5x	34.8%	—	—	$128.75
TGTXTG Therapeutics, Inc.	D	B	B	10.3x	76.1%	82.4%	—	$53.97
AXSMAxsome Therapeutics, Inc	D	B	C	10.6x	56.9%	93.2%	—	$157.14
ARWRArrowhead Research Corporation	D	A	C	11.8x	16.9%	—	—	$55.90
ABVXAbivax SA American Depositary Shares	—	—	C	—	—	—	—	$88.13
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	5995.2x	—	—	—	$79.90
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	8.2x	-7.5%	98.2%	—	$42.94
ALKSAlkermes Inc. plc	D	C	B	4.1x	10.8%	84.6%	—	$41.22
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	789.2x	—	—	—	$241.76
AMRXAmneal Pharmaceuticals, Inc. Class A Common Stock	D	C	A	2.0x	9.3%	39.3%	-18.4%	$19.18
KNSAKiniksa Pharmaceuticals International, plc Class A Ordinary Shares	D	B	A	7.3x	58.9%	89.8%	—	$78.59
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	24.7x	53.5%	70.9%	—	$86.17
LGNDLigand Pharmaceuticals Inc.	D	B	B	20.3x	54.9%	95.4%	—	$295.54
BLTEBelite Bio, Inc American Depositary Shares	—	—	B	—	—	—	—	$142.78

About Pharming Group N.V. ADS, each representing 10 ordinary shares

Pharming Group is a biopharmaceutical company focused on rare and life-threatening diseases with unmet medical needs. It markets RUCONEST for hereditary angioedema (HAE) and Joenja (leniolisib) for activated phosphoinositide 3-kinase delta syndrome, supported by a pipeline of biologic and small-molecule therapies in development.